Lundbeck and EVERSANA Form Strategic Partnership for AI-Powered Commercialization
Pharmaceutical company Lundbeck and commercialization services provider EVERSANA have announced a strategic partnership to deploy EVERSANA's AI platform and enhance Lundbeck's commercialization capabilities.
Lundbeck, a global pharmaceutical company, has entered into a strategic partnership with EVERSANA, a life sciences commercialization company. The collaboration aims to leverage artificial intelligence (AI) to advance Lundbeck's commercialization strategies.
The partnership will see Lundbeck expand the deployment of EVERSANA's AI Agency platform. This initiative is intended to support Lundbeck's "Focused Innovator" strategy and its ambitions in integrating technology with pharmaceutical development and market access.
EVERSANA's AI-powered platform provides analytical tools and capabilities designed to optimize the commercialization of pharmaceutical products. The integration is expected to enable Lundbeck to enhance market targeting, develop more personalized patient support, and improve overall commercial efficiency.
This collaboration signifies a move by Lundbeck to incorporate advanced AI technologies into its global operations, with the goal of accelerating the delivery of its therapies to patients. Both companies anticipate that AI will play a significant role in the future of pharmaceutical commercialization.